511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial

C. Santos Vivas, J. Vidal Barrull, C. Fernandez Rodriguez, F. Salvà Ballabrera, Vicente Alonso-Orduña, R. Garcia-Carbonero, F. Losa, N. Tarazona Llavero, M.J. Safont Aguileria, F. Rivera Herrero, L. Layos Romero, M.J. Ortiz Morales, Antonieta Salud, Julia Alcaide, D. Paez, Xavier Hernández‐Yagüe, Rafael Álvarez-Gallego, José Rafael Vera Vera, B. Bellosillo Paricio, C. Montagut Viladot